Entry EDSS ⩽3.5 subgroup | Entry EDSS>3.5 subgroup | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Two year difference | AUCCHANGE(in EDSS-years) | Two year difference | AUCCHANGE(in EDSS-years) | ||||||||
Median | Mean | Median | Mean | Median | Mean | median | mean | ||||
(A) EDSS: | |||||||||||
IFNβ-1a 44 μg (3×/week) | 0 (1.0) | +0.21 (1.13) | +0.04 (1.79) | +0.23 (1.58) | 0 (1.0) | +0.38 (1.15) | +0.26 (1.21) | +0.83 (1.79) | |||
IFNβ-1a 22 μg (3×/week) | 0 (1.0) | +0.12 (1.27) | +0.05 (1.79) | +0.20 (1.79) | +0.5 (1.0) | +0.69 (1.30) | 0 (2.10) | +1.07 (2.20) | |||
Placebo | +0.5 (1.25) | +0.37 (1.18) | +0.38 (1.66) | +0.64 (1.84) | +0.5 (2.0) | +1.14 (1.59) | +1.07 (3.00) | +1.78 (2.28) | |||
Two year difference | AUCCHANGE(in SNRS-years) | Two year difference | AUCCHANGE(in SNRS-years) | ||||||||
Median | Mean | Median | Mean | Median | Mean | median | mean | ||||
(B) SNRS: | |||||||||||
IFNβ-1a 44 μg (3×/week) | 0 (7) | −1.34 (7.66) | 0 (12.68) | −1.11 (11.54) | −3 (16) | +0.07 (9.67) | +0.81 (18.74) | +0.46 (12.25) | |||
IFNβ-1a 22 μg (3×/week) | 0 (9) | −1.57 (9.15) | −0.32 (9.51) | −1.15 (11.49) | −2 (14) | −2.49 (9.12) | −0.05 (18.93) | −2.82 (15.09) | |||
Placebo | −1 (7) | −2.49 (8.48) | −1.46 (9.86) | −2.34 (11.22) | −4 (12) | −7.00 (11.68) | −7.86 (19.65) | −8.67 (16.89) | |||
Two year difference | AUCCHANGE(in AI-years) | Two year difference | AUCCHANGE(in AI-years) | ||||||||
Median | Mean | Median | Mean | Median | Mean | median | mean | ||||
(C) AI | |||||||||||
IFNβ-1a 44 μg (3×/week) | 0 (1) | +0.19 (0.93) | 0 (0.86) | +0.16 (1.25) | 0 (1) | +0.5 (1.07) | +0.18 (1.61) | +0.69 (1.54) | |||
IFNβ-1a 22 μg (3×/week) | 0 (1) | +0.34 (1.13) | +0.10 (0.85) | +0.41 (1.38) | +1 (1) | +0.97 (1.59) | +0.61 (1.57) | +1.10 (2.27) | |||
Placebo | 0 (1) | +0.29 (1.03) | 0 (1.27) | +0.48 (1.44) | +1 (1) | +1.36 (2.18) | +1.13 (1.81) | +1.65 (2.34) |